The evolution of fluoropyrimidine therapy: From intravenous to oral

Oncologist

Volumn 6, Issue SUPPL. 4, 2001, Pages 3-11

  Hoff, Paulo M ^a   Cassidy, J E M ^b   Schmoll, Hans Joachim ^c  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

5 FU; Capecitabine; Colorectal cancer; Fluoropyrimidines

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; THYMIDINE PHOSPHORYLASE;

ALOPECIA; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; STOMATITIS;

EID: 0034798771     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_4-3     Document Type: Conference Paper

References (39)

1. Large-bowel cancer - The current status of treatment
2. Therapy of advanced gastrointestinal cancer with the nitrosoureas
3. Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bischloroethyl nitrosourea in colon cancer
4. 5 FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: A Southwest Oncology Group Study
5. Chemotherapy of gastrointestinal cancer
6. Mitomycin C: A review
7. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
8. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
9. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
10. Chemotherapy for colorectal cancer with a combination of PALA and 5-FU
11. Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer
12. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO)
13. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study
14. Sequential methotrexate and 5-fluorouracil: Improved response rate in metastatic colorectal cancer
15. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
16. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer evidence in terms of response rate
17. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
18. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
19. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
20. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
21. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
22. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
23. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
24. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
25. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
26. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
27. International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC)
28. North American phase III study of oral eniluracil (EU) plus oral 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC)
29. 14C-labelled drug
30. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
31. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
32. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
33. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
34. Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: Results of a large phase III study
35. Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomised, phase III studies
36. Effective dose-modification (DM) scheme for the management of toxicities with capecitabine therapy: Data from metastatic colorectal cancer (mCRC) phase III trials
37. Prediction of creatinine clearance from serum creatinine